These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 17196564

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
    Tronci E, Simola N, Borsini F, Schintu N, Frau L, Carminati P, Morelli M.
    Eur J Pharmacol; 2007 Jul 02; 566(1-3):94-102. PubMed ID: 17445798
    [Abstract] [Full Text] [Related]

  • 3. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S, Jackson MJ, Smith LA, Stockwell K, Johnson L, Carminati P, Jenner P.
    Eur J Pharmacol; 2006 Sep 28; 546(1-3):82-7. PubMed ID: 16925991
    [Abstract] [Full Text] [Related]

  • 4. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
    Pinna A, Fenu S, Morelli M.
    Synapse; 2001 Mar 01; 39(3):233-8. PubMed ID: 11284438
    [Abstract] [Full Text] [Related]

  • 5. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V, Sosti V, Rubio A, Barbanoj M, Rodríguez-Alvarez J, Kulisevsky J.
    Eur J Pharmacol; 2007 Dec 08; 576(1-3):83-90. PubMed ID: 17888901
    [Abstract] [Full Text] [Related]

  • 6. Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
    Stasi MA, Minetti P, Lombardo K, Riccioni T, Caprioli A, Vertechy M, Di Serio S, Pace S, Borsini F.
    Eur J Pharmacol; 2015 Aug 15; 761():353-61. PubMed ID: 25936513
    [Abstract] [Full Text] [Related]

  • 7. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
    Lane EL, Cheetham SC, Jenner P.
    Exp Neurol; 2006 Feb 15; 197(2):284-90. PubMed ID: 16005456
    [Abstract] [Full Text] [Related]

  • 8. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1998 Jun 15; 151(2):334-42. PubMed ID: 9628768
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours.
    Lane EL, Cheetham SC, Jenner P.
    Eur J Neurosci; 2005 Jan 15; 21(1):179-86. PubMed ID: 15654855
    [Abstract] [Full Text] [Related]

  • 11. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
    Pinna A, Pontis S, Borsini F, Morelli M.
    Synapse; 2007 Aug 15; 61(8):606-14. PubMed ID: 17476684
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
    Sarre S, Lanza M, Makovec F, Artusi R, Caselli G, Michotte Y.
    Eur J Pharmacol; 2008 Apr 28; 584(2-3):297-305. PubMed ID: 18342306
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Blockade of A2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata.
    Carta AR, Tabrizi MA, Baraldi PG, Pinna A, Pala P, Morelli M.
    Exp Neurol; 2003 Dec 28; 184(2):679-87. PubMed ID: 14769359
    [Abstract] [Full Text] [Related]

  • 18. L-dopa-induced desensitization depends on 5-hydroxytryptamine imbalance in hemiparkinsonian rats.
    Kääriäinen TM, García-Horsman JA, Piltonen M, Männistö PT.
    Neuroreport; 2009 Feb 18; 20(3):313-8. PubMed ID: 19188858
    [Abstract] [Full Text] [Related]

  • 19. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
    Kääriäinen TM, García-Horsman JA, Piltonen M, Huotari M, Männistö PT.
    Basic Clin Pharmacol Toxicol; 2008 Mar 18; 102(3):300-7. PubMed ID: 17973898
    [Abstract] [Full Text] [Related]

  • 20. CSC counteracts l-DOPA-induced overactivity of the corticostriatal synaptic ultrastructure and function in 6-OHDA-lesioned rats.
    Huang YX, Luo WF, Li D, Hu WD, Liu CF.
    Brain Res; 2011 Feb 28; 1376():113-21. PubMed ID: 21195062
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.